1/4 Must-read 🧵. Molnupiravir could be a catastrophe, breeding a nightmarish panoply of variants. Approval would be insane.
"MOV approval is most momentous decision the FDA will make in this epidemic, maybe in FDA history, maybe even in the entire history of pharmaceuticals."
"MOV approval is most momentous decision the FDA will make in this epidemic, maybe in FDA history, maybe even in the entire history of pharmaceuticals."
https://twitter.com/michaelzlin/status/1473818094573441030
2/4 Molnupiravir works by causing SARS-CoV-2 to undergo so many mutations that it ceases to function. Except it doesn't always work. And when it doesn't, virus with potentially beneficial mutations could survive, be passed on, and haunt the world.
https://twitter.com/michaelzlin/status/1473834417751658496
3/4 It's not even clear if molnupiravir works at all—in the Delta era phase of its trial, it proved almost totally useless. Perhaps it doesn't work against rapidly replicating variants like Delta & Omicron. nature.com/articles/d4158… 
4/4 Huge red flag. Merck says no virus survived in health subjects but is silent on whether live virus survived in weaker patients. It's a dead giveaway: some of these patients harbored live virus—i.e. molnupiravir transformed them into variant factories.
https://twitter.com/michaelzlin/status/1473846586874613760
5/4 This may be a coincidence, but I still think it's worth mentioning: "There are 173 Molnupiravir trial sites around the world, including 4 in Gauteng."
Altogether, there were 12 molnupiravir trial sites in South Africa.
h/t @bicidiario
Altogether, there were 12 molnupiravir trial sites in South Africa.
h/t @bicidiario
https://twitter.com/C_A_Gustave/status/1465073035732570114
• • •
Missing some Tweet in this thread? You can try to
force a refresh
